NOTE 3 – STOCK OPTIONS

On March 5, 2023, the Board of the Company determined that in the event that the Company’s stock is listed on the Nasdaq Stock Market, then one half of the awarded but unvested option grants made in each of August 2021 and in August 2022, including to officers, directors, will immediately vest at such time. In addition, the Board also determined to provide that following the termination of services by an officer, director or a selected service provider for any reason other than cause, such person shall have a one year period from the date of termination to exercise any option that was vested at the time of the termination of services.

The following table presents the Company’s stock option activity for employees and directors of the Company for the period ended March 31, 2025:

 SCHEDULE OF STOCK OPTION ACTIVITY

The stock options outstanding as of March 31, 2025, have been separated into exercise prices, as follows:

 SCHEDULE OF STOCK OPTIONS OUTSTANDING

Compensation expense recorded by the Company in respect of its stock-based compensation awards for the period ended March 31, 2025 and 2024 was $31 thousand and $91 thousand, respectively, and are included in General and Administrative expenses in the Statements of Operations.

As of March 31, 2025, there was $21 thousand of total unrecognized compensation cost related to non-vested options. The cost is expected to be recognized over a weighted average period of 0.5 years.

The aggregate intrinsic value of the awards outstanding as of March 31, 2025 is $0. These amounts represent the total intrinsic value, based on the Company’s stock price of $0.0115 as of March 31, 2025, less the weighted exercise price.

CITRINE GLOBAL, CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)